Current Neuro-Oncology

Volume 28 Number 24
31 August 2026

Home > Publications > Current Neuro-Oncology > Volume 28, Year 2026 > Number 24, 31 August

Zhu W, Rao J, Hu G, Wang R, Luo X, Li Q.
Tumor treating fields plus temozolomide maintenance after radiochemotherapy in Chinese grade 4 gliomas: Efficacy and predictive biomarkers.
Neurooncol Adv. 2026 Jul 23;8(1):vdag194. doi: 10.1093/noajnl/vdag194. PMID: 42630691. ˍ

Souat S, El Azhary K, Bourdoukh S, Kone AS, Qandouci A, Harmak Z, Choukri K, Lakhdar A, Badou A.
Elevated BTLA Expression Correlates with an Immunosuppressive Microenvironment and Defines Dysfunctional Circulating T Cells in Human Glioblastoma.
Med Sci (Basel). 2026 Jul 25;14(4):433. doi: 10.3390/medsci14040433. PMID: 42646567. ˍ

Haedenkamp T, Fischl A, Gerken M, Rothhammer-Hampl T, Fassbender A, Klein V, Liu I, Layer K, Suboh A, Luger AL, Mildenberger I, Weller J, Kebir S, Schmidt T, Zeyen T, Glas M, Herrlinger U, Onken J, Platten M, Schmidt-Graf F, Steinbach JP, Linker R, Riemenschneider MJ, Proescholdt M, Maurer J, Bumes E, Hau P.
Lomustine with or without procarbazine in recurrent glioblastoma-A propensity score matching analysis.
Neurooncol Adv. 2026 Jul 31;8(1):vdag197. doi: 10.1093/noajnl/vdag197. PMID: 42639298. ˍ

Tang PLY, Smits M, van Werkhoven ED, Nout RA, Warnert EAH, Méndez Romero A.
Recurrence distance analysis for clinical target volume optimization in glioblastoma.
Clin Transl Radiat Oncol. 2026 Aug 12;61:101258. doi: 10.1016/j.ctro.2026.101258. PMID: 42633158. ˍ

Jin D, DiVita B, Reid A, Love C, Figg JW, Francis C, Falceto Font L, Long-James K, Hilferty D, Stansbury S, Morikawa N, Sebastian M, Boulant S, Mitchell DA, Flores C.
Dendritic Cell Dysfunction Underlies Immune Escape After Adoptive Cellular Therapy in Glioblastoma.
Cancers (Basel). 2026 Aug 18;18(16):2669. doi: 10.3390/cancers18162669. PMID: 42649980. ˍ